发明申请
US20110184000A1 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS
有权
1-环己基-1,5-二氢吡喃并[3,4-D]吡啶并[4-a]衍生物及其作为PDE9A调节剂的用途
- 专利标题: 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS
- 专利标题(中): 1-环己基-1,5-二氢吡喃并[3,4-D]吡啶并[4-a]衍生物及其作为PDE9A调节剂的用途
-
申请号: US12935686申请日: 2009-04-01
-
公开(公告)号: US20110184000A1公开(公告)日: 2011-07-28
- 发明人: Riccardo Giovannini , Cornelia Dorner-Ciossek , Christian Eickmeier , Dennis Fiegen , Thomas Fox , Klaus Fuchs , Niklas Heine , Holger Rosenbrock , Gerhard Schaenzle
- 申请人: Riccardo Giovannini , Cornelia Dorner-Ciossek , Christian Eickmeier , Dennis Fiegen , Thomas Fox , Klaus Fuchs , Niklas Heine , Holger Rosenbrock , Gerhard Schaenzle
- 申请人地址: DE Ingelheim am Rhein
- 专利权人: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 当前专利权人: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- 当前专利权人地址: DE Ingelheim am Rhein
- 优先权: EP08153987.6 20080402
- 国际申请: PCT/EP09/53907 WO 20090401
- 主分类号: A61K31/519
- IPC分类号: A61K31/519 ; C07D487/04 ; A61P25/28
摘要:
The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with is a mono-, bi- or tri-cyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of —S(O)r— with r being 0, 1 or 2, and—said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and—said heterocyclyl group is bound to the scaffold by said 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.